**Intervention period** (24 months)

- Birth Study enrolment
- Baseline assessment

**Follow up** (6 months)

- End of intervention
- End of follow up

* exacerbation episodes

**Subsequent assessments (every 3-4 months)**

**Birth to enrolment:**
- Past medical history
- Number of exacerbations
- Birth weight

**Baseline assessment:**
- Demographics
- Cough
- Clinical assessment
- Height and weight
- Deep nasal swab
- Diagnosis

**Subsequent assessments:**
- Cough
- Clinical assessment
- Height and weight
- Deep nasal swab
- Diagnosis

**Primary outcomes:**
- Counts of exacerbation episodes (enrolment to end of intervention)
- Time to exacerbation (enrolment to 1st exacerbation episode)

**Secondary outcomes:**
- Length of exacerbation episodes (length of hospital stay)
- Severity of exacerbation episodes (hospitalised vs. treated at home)
- Growth (z-scores at baseline vs. at the end of intervention)
- Overall well being (proportion of visits where wet cough was present)
- Serious adverse effects
- Antibiotic resistance by respiratory bacterial pathogens (*Streptococcus pneumoniae*, *Haemophilus influenzae*, *Moraxella catarrhalis*, *Staphylococcus aureus* and *Streptococcus pyogenes*) at baseline and at the end of the intervention against macrolide and beta-lactam antibiotics.